Search

Your search keyword '"Siguret V"' showing total 326 results

Search Constraints

Start Over You searched for: Author "Siguret V" Remove constraint Author: "Siguret V"
326 results on '"Siguret V"'

Search Results

3. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

4. Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021): From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care (SFAR)

5. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

7. PB0491 Patients from Different Settings Receiving Unfractionated Heparin (DEXHEP Study): Impact of PF4 on Anti-Xa Levels

16. Toxic iron species in lower-risk myelodysplastic syndrome patients : course of disease and effects on outcome

17. Étude prospective des événements thromboemboliques veineux chez les patients hospitalisés pour COVID-19 : anomalies associées de l’hémostase et suivi clinicobiologique à 6 mois

19. Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021)

20. Leucocytes, D-dimères et Ferritinémie comme Facteurs Prédictifs Indépendants d’Embolie Pulmonaire suspectée à l’admission chez les patients COVID-19 hospitalisés hors réanimation : étude rétrospective multicentrique française CLOTVID

21. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

22. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

30. Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis

34. Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*.

40. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications.

48. Les cliniques d’anticoagulants sont-elles efficaces en France ? Évaluation des performances de six cliniques dans la gestion des traitements par antivitamines K

49. Les cliniques d’anticoagulants sont-elles efficaces dans la gestion des traitements par antivitamines K en France ?

Catalog

Books, media, physical & digital resources